Moderna Ships 100 Millionth Dose of COVID-19 Vaccine to the U.S. Government
We are proud to announce today that Moderna has shipped the 100 millionth dose of the Moderna COVID-19 Vaccine to the United States government. This is a most heartening milestone.
In a year that has been both historic and life-changing for almost everyone, so many of us have come together across business, government and civil society to make what is proving to be a profound impact. We knew from the very beginning that no one could do this alone. The Moderna team feels a deep sense of responsibility and pride in having been able to be part of the solution.
Thank you to the many millions of people who have already put their confidence and trust in Moderna’s science and in our COVID-19 vaccine. You are our friends, our family, our coworkers, our neighbors, and we are humbled by the opportunity to help you. We are extremely grateful to the tens of thousands of participants in our clinical studies, as well as the staff at clinical trial sites who have been on the front lines of the fight against the virus.
Special thanks to our dedicated team of employees, to our suppliers, to our collaborators in the government and to our U.S. manufacturing partners, Lonza and Catalent, for extraordinary, tireless work. We are grateful to have worked with you as we have sought to combat this pandemic.
In 10 years since our inception, Moderna has focused on our Mission to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. We have advanced messenger RNA (mRNA) technology from the realm of revolutionary scientific possibility, to commercial production at unprecedented speed and scale.
It is our responsibility as an industry, as a company, and as global citizens to work together to try to end this pandemic, and to continue to save and improve lives. There is still far to go and much to do in the fight against this devastating virus. Along with our partners, our teams are working as hard as we can to manufacture with high quality as many doses of the vaccine as possible because we know that each additional dose we make will be used to protect one more life.
We are continuing to ramp up production and expect to deliver 40-50 million more doses per month to the U.S. government in April, May, June and July, in keeping with our commitments. We are working diligently to ramp up our supplies outside of the U.S. as well.
We remain committed to defeating the global COVID-19 pandemic. There is also far to go, and much for us to do as a company in addressing other diseases. We are closer than ever before to launching several first-in-class medicines for patients where there are no treatments today.
Thank you for your trust and support.
This post contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Company’s development of a vaccine (mRNA-1273) to protect against the SARS-CoV-2 virus, which causes COVID-19; increases in production volumes over the coming months; and the number of doses to be delivered to the U.S. Government and the anticipated timeline for those deliveries. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.
Moderna COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. Moderna COVID-19 Vaccine is investigational and not approved by FDA.
For more information about COVID-19 and the recommendations of the Centers for Disease Control, please visit https://www.cdc.gov/vaccines/covid-19/. For more about Moderna, please visit www.modernatx.com